2 years ago

CanSense Secures £1.5 Million for AI-Powered Bowel Cancer Blood Test

  • CanSense, a Swansea-based biotech startup, has raised £1.5 million in funding to advance its AI-powered blood test for early bowel cancer detection

  • The funding was secured from Mercia, the Development Bank of Wales, and Nonacus

  • CanSense's technology aims to provide a less invasive alternative to traditional methods, potentially reducing the burden on the NHS and improving early detection rates for bowel cancer.

      • ProblemHealthcare

      "Bowel cancer is the second most common cause of cancer deaths in the UK, and current detection methods like colonoscopies are expensive and invasive. The NHS spends £300m annually on colonoscopies, with less than 10% resulting in cancer detection."

      Solution

      "CanSense has developed a blood test that uses laser light and AI to detect bowel cancer at an early stage. This test is less invasive than colonoscopies and could help reduce the burden on the NHS."

      Covered on